<DOC>
	<DOC>NCT00725777</DOC>
	<brief_summary>Patients with non-falciparum infection will be given artemether-lumefantrine for three days and will be followed up for 28 days. Besides efficacy and safety evaluations a substudy on immunology will be performed.</brief_summary>
	<brief_title>Treatment of Non-falciparum Malaria</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Male or female patients between the age of 6 months and 60 years and with a minimum of 5kg bodyweight Presence of uncomplicated malaria confirmed by: i)fever or history of fever in the previous 4 days, and ii)positive microscopy of P. malariae or P. ovale or mixed infection with P.falciparum with parasite density &gt; 50200000/Î¼l of blood Written informed consent Patients with presence of other clinical conditions requiring hospitalization Presence of other febrile conditions Presence of significant anemia, defined by hemoglobin &lt; 7g/dl Known history of hypersensitivity,allergic or adverse reactions to artemether or lumefantrine Intake of any antimalarial or antibiotics with known antimalarial activity in the preceding 2 weeks Pregnant and breast feeding females</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>